ClinicalTrials.gg
CompletedNCT00619710Updated Sep 1, 2017

Complicated Skin and Skin Structure Infections

A Phase 3 interventional study of Meropenem and Imipenem-cilastatin in Skin Infection, Abscess and Cellulitis, sponsored by Pfizer. Completed. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2017-09-01.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Study summary

The purpose of this study is to demonstrate the non-inferiority of meropenem (Merrem) and imipenem in hospitalised subjects with complicated skin and skin structure infections.

02

Conditions studied

  • Skin Infection
  • Abscess
  • Cellulitis

Keywords

  • skin infections
  • MERREM
  • PRIMAXIN IV
  • complex abscess
  • perirectal abscess
  • wound infections
  • infected ischemic/diabetic ulcers
  • cellulitis
  • Meropenem
  • Imipenem-cilastatin
03

In context

Cellulitis

160 studies on the registry are indexed under Cellulitis; 14 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 157 across 124 interventional studies indexed under Cellulitis.

Browse Cellulitis studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects are hospitalized males and females, aged 13 years or older, with clinical evidence of complicated skin and skin structure bacterial infection with material suitable for culture from 1 primary site of infections
  • Within 72 hours before enrollment or at the time of enrollment, all subjects must provide an appropriate specimen for culture and susceptibility testing
  • Subjects who have been given prior antibacterial therapy within 14 days of trial entry may be entered only if a culture is obtained showing persistence of a pathogen in blood or at the site of infection

Exclusion criteria

Exclusion Criteria:

  • Subjects with a known or suspected to cephalosporins, penicillins, or carbapenems
  • Subjects with a history of seizure disorders or subjects currently receiving antiepileptic medication
  • Subjects with underlying infections or conditions which would interfere with evaluation of this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    1

    Meropenem

    Drug: Meropenem

  • Active comparator
    2

    Imipenem-cilastatin

    Drug: Imipenem-cilastatin

Interventions

  • Intravenous

    Also known as: Merrem

  • DrugImipenem-cilastatin

    Intravenous

    Also known as: Primaxin

06

What researchers measure

Primary outcomes

  1. The primary measure is clinical response after all antibacterial treatment is stopped).

    Time frame: 7-28 days

Secondary outcomes

  1. clinical and microbiological response

    Time frame: Twice 3-28 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2001, a primary completion of Dec 2003 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2008
First posted
Feb 21, 2008
Start
Feb 2001
Primary completionActual
Dec 2003
CompletionActual
Apr 2004
Last update
Sep 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00619710
Lead sponsor
Pfizer
First posted
Feb 21, 2008
Start date
Feb 2001
Primary completion
Dec 2003
Completion
Apr 2004
Last update
Sep 1, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meropenem

Start the discussion